<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: Early detection of colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> at high risk of progression and early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is an effective approach to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> rates </plain></SENT>
<SENT sid="1" pm="."><plain>Current screening methods lack specificity as they detect many <z:mpath ids='MPATH_270'>adenomas</z:mpath> that will never progress to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The authors aimed to identify cell surface protein biomarkers with extracellular domains that could be targeted for molecular imaging and discriminate low-risk <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:mpath ids='MPATH_458'>normal</z:mpath> colon from high-risk <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Cell surface proteins of five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were biotinylated, isolated and analysed by in-depth proteomics using gel electrophoresis and nanoliquid chromatography coupled to tandem mass spectrometry </plain></SENT>
<SENT sid="4" pm="."><plain>Differential expression in <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> was based on <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression and verified by immunohistochemical staining of tissue microarrays </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In total, 2609 proteins were identified in the cell surface fractions </plain></SENT>
<SENT sid="6" pm="."><plain>Of these, 44 proteins were selected as promising cell surface candidate biomarkers for <z:mpath ids='MPATH_270'>adenoma</z:mpath>-to-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression based on the following criteria: protein identification in at least four out of five cell lines, a predicted (trans)membrane location and increased <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> compared to <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Increased protein expression in high-risk <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> compared to low-risk <z:mpath ids='MPATH_270'>adenomas</z:mpath> was confirmed by immunohistochemistry for <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter type 1 (gene symbol SLC2A1; p&lt;0.00001) and prion protein (gene symbol PRNP; p&lt;0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: This study revealed <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter type 1, prion protein and 42 other cell surface candidate biomarkers for <z:mpath ids='MPATH_270'>adenoma</z:mpath>-to-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression that could potentially serve as targets for emerging molecular imaging modalities like optical imaging, ¹⁹F-MRI and <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography </plain></SENT>
</text></document>